nach oben

Erschienen in:

01.03.2012 | Original Article

The Feasibility of ¹⁸F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer

verfasst von: Seol Hoon Park, Jin-Sook Ryu, Seung-Jun Oh, Seung-Il Park, Yong Hee Kim, Hoon-Yong Jung, Gin Hyug Lee, Ho Jun Song, Jong Hoon Kim, Ho-Young Song, Kyoung Ja Cho, Sung-Bae Kim

Erschienen in: Nuclear Medicine and Molecular Imaging | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to determine whether ¹⁸F-fluorothymidine (FLT) PET is feasible for the early prediction of tumor response to induction chemotherapy followed by concurrent chemoradiotherapy in patients with esophageal cancer.

Methods

This study was prospectively performed as a collateral study of “randomized phase II study of preoperative concurrent chemoradiotherapy with or without induction chemotherapy with S-1/oxaliplatin in patients with resectable esophageal cancer”. ¹⁸F-FLT positron emission tomography (PET) images were obtained before and after two cycles of induction chemotherapy, and the percent change of maximum standardized uptake value (SUVmax) was calculated. All patients underwent esophagography, gastrofiberoscopy, endoscopic ultrasonography (EUS), computed tomography (CT) and ¹⁸F-fluorodeoxyglucose (FDG) PET at baseline and 3–4 weeks after completion of concurrent chemoradiotherapy. Final tumor response was determined by both clinical and pathologic tumor responses after surgery.

Results

The 13 patients for induction chemotherapy group were enrolled until interim analysis. In a primary tumor visual analysis, the tumor detection rates of baseline ¹⁸F-FLT and ¹⁸F-FDG PET were 85% and 100%, respectively. The tumor uptakes on ¹⁸F-FLT PET were lower than those of ¹⁸F-FDG PET. Among nine patients who completed second ¹⁸F-FLT PET, eight patients were responders and one patient was a non-responder in the assessment of final tumor response. The percent change of SUVmax in responders ranged from 41.2% to 79.2% (median 57.1%), whereas it was 10.2% in one non-responder.

Conclusion

The percent change of tumor uptake in ¹⁸F-FLT PET after induction chemotherapy might be feasible for early prediction of tumor response after induction chemotherapy and concurrent chemoradiotherapy in patients with esophageal cancer.

Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P, et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology. 2005;236:841–51.PubMedCrossRef

Malaisrie SC, Hofstetter WL, Correa AM, Ajani JA, Komaki RR, Rice DC, et al. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006;107:967–74.PubMedCrossRef

Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.PubMedCrossRef

Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, et al. Staging of esophageal cancer with ¹⁸F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol. 1997;168:417–24.PubMed

Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–65.PubMed

Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692–8.PubMedCrossRef

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N. Ido T Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–80.PubMed

Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med. 1991;32:1485–90.PubMed

Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–6.PubMedCrossRef

10.

Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: ¹⁸F-FLT versus ¹⁸F-FDG. J Nucl Med. 2003;44:1426–31.PubMed

11.

Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumors with ¹⁸F-FLT PET: comparison with ¹⁸F-FDG. J Nucl Med. 2005;46:945–52.PubMed

12.

Chao KS. Functional imaging for early prediction of response to chemoradiotherapy: 3′-deoxy-3′-¹⁸F-fluorothymidine positron emission tomography—a clinical application model of esophageal cancer. Semin Oncol. 2006;33:S59–63.PubMedCrossRef

13.

Edge SB. Compton CC The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.PubMedCrossRef

14.

Lee SJ, Oh SJ, Chi DY, Kil HS, Kim EN, Ryu JS, et al. Simple and highly efficient synthesis of 3′-deoxy-3′-[¹⁸F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent. Eur J Nucl Med Mol Imaging. 2007;34:1406–9.PubMedCrossRef

15.

Lordick F, Ott K, Krause BJ. New trends for staging and therapy for localized gastroesophageal cancer: the role of PET. Ann Oncol. 2010;21 Suppl 7:vii294–9.PubMedCrossRef

16.

Klaeser B, Nitzsche E, Schuller JC, Koberle D, Widmer L, Balmer-Majno S, et al. Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie. 2009;32:724–30.PubMedCrossRef

17.

Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61–77. quiz 150–151.PubMed

18.

Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q. Aboagye EO Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[¹⁸F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005;65:4202–10.PubMedCrossRef

19.

Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, et al. Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[¹⁸F]-fluoro-L-thymidine ([¹⁸F]FLT) positron emission tomography (PET). PLoS One. 2008;3:e3908.PubMedCrossRef

20.

Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36–42.PubMedCrossRef

21.

Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S. Aboagye EO Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[¹⁸F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339–47.PubMedCrossRef

22.

Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [¹⁸F]fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714–21.PubMedCrossRef

23.

Yue J, Chen L, Cabrera AR, Sun X, Zhao S, Zheng F, et al. Measuring tumor cell proliferation with ¹⁸F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med. 2010;51:528–34.PubMedCrossRef

24.

Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, et al. PET imaging with [¹⁸F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878–83.PubMedCrossRef

25.

Herrmann K, Wieder HA, Buck AK, Schoffel M, Krause BJ, Fend F, et al. Early response assessment using 3′-deoxy-3′-[¹⁸F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin’s lymphoma. Clin Cancer Res. 2007;13:3552–8.PubMedCrossRef

26.

van Westreenen HL, Cobben DC, Jager PL, van Dullemen HM, Wesseling J, Elsinga PH, et al. Comparison of ¹⁸F-FLT PET and ¹⁸F-FDG PET in esophageal cancer. J Nucl Med. 2005;46:400–4.PubMed

27.

Francis DL, Visvikis D, Costa DC, Arulampalam TH, Townsend C, Luthra SK, et al. Potential impact of [¹⁸F]3′-deoxy-3′-fluorothymidine versus [¹⁸F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging. 2003;30:988–94.PubMedCrossRef

28.

Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, et al. Comparison of ¹⁸F-FLT PET and ¹⁸F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2008;35:236–45.PubMedCrossRef

Titel: The Feasibility of 18F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer
verfasst von: Seol Hoon Park
Jin-Sook Ryu
Seung-Jun Oh
Seung-Il Park
Yong Hee Kim
Hoon-Yong Jung
Gin Hyug Lee
Ho Jun Song
Jong Hoon Kim
Ho-Young Song
Kyoung Ja Cho
Sung-Bae Kim
Publikationsdatum: 01.03.2012
Verlag: Springer-Verlag
Erschienen in: Nuclear Medicine and Molecular Imaging / Ausgabe 1/2012
Print ISSN: 1869-3474
Elektronische ISSN: 1869-3482
DOI: https://doi.org/10.1007/s13139-011-0118-4

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The Feasibility of ¹⁸F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer

Abstract

Purpose

Methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Solitary Cerebellar Metastasis of Cecal Cancer, Visualized Using F-18 FDG PET/CT

Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study

Effect of Animal Condition and Fluvoxamine on the Result of [18F]N-3-Fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) Nortropane ([18F]FP-CIT) PET Study in Mice

Optical Imaging for Stem Cell Differentiation to Neuronal Lineage

Development of a 68Ga-Fluorinated Porphyrin Complex as a Possible PET Imaging Agent

Prosthesis-Related Abscess on In-111 Leukocyte SPECT/CT Imaging